MedTrace Logo

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

NCT01027013 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2012-01-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of rebamipide 2% suspension for the treatment of patients with dry-eye.

Conditions

  • Dry Eye Syndromes
  • Keratoconjunctivitis Sicca

Interventions

DRUG

rebamipide 2% ophthalmic suspension

Instill one drop in each eye four times daily for 12 weeks.

DRUG

placebo eye drops

Instill one drop in each eye four times daily for 12 weeks.

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Kubota Vision Inc.

    lead INDUSTRY

Principal Investigators

  • Nancy Boman, MD, PhD · Kubota Vision Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-10-31
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01027013 on ClinicalTrials.gov